175 related articles for article (PubMed ID: 32152202)
1. Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.
Yang RK; Kuznetsov IB; Ranheim EA; Wei JS; Sindiri S; Gryder BE; Gangalapudi V; Song YK; Patel V; Hank JA; Zuleger C; Erbe AK; Morris ZS; Quale R; Kim K; Albertini MR; Khan J; Sondel PM
Clin Cancer Res; 2020 Jul; 26(13):3296-3306. PubMed ID: 32152202
[TBL] [Abstract][Full Text] [Related]
2. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
Albertini MR; Yang RK; Ranheim EA; Hank JA; Zuleger CL; Weber S; Neuman H; Hartig G; Weigel T; Mahvi D; Henry MB; Quale R; McFarland T; Gan J; Carmichael L; Kim K; Loibner H; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2018 Oct; 67(10):1647-1658. PubMed ID: 30073390
[TBL] [Abstract][Full Text] [Related]
3. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
[TBL] [Abstract][Full Text] [Related]
4. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
Ribas A; Kirkwood JM; Atkins MB; Whiteside TL; Gooding W; Kovar A; Gillies SD; Kashala O; Morse MA
J Transl Med; 2009 Jul; 7():68. PubMed ID: 19640287
[TBL] [Abstract][Full Text] [Related]
6. Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial.
Khammari A; Nguyen JM; Leccia MT; Guillot B; Saiagh S; Pandolfino MC; Knol AC; Quéreux G; Chiffolettau A; Labarrière N; Dréno B
Cancer Immunol Immunother; 2020 Aug; 69(8):1663-1672. PubMed ID: 32306076
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
Hank JA; Gan J; Ryu H; Ostendorf A; Stauder MC; Sternberg A; Albertini M; Lo KM; Gillies SD; Eickhoff J; Sondel PM
Clin Cancer Res; 2009 Sep; 15(18):5923-30. PubMed ID: 19737959
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients.
Yuan Y; Zhu Z; Lan Y; Duan S; Zhu Z; Zhang X; Li G; Qu H; Feng Y; Cai H; Song Z
Front Immunol; 2021; 12():659444. PubMed ID: 34040608
[TBL] [Abstract][Full Text] [Related]
10. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
11. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
12. The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma.
Song LB; Luan JC; Zhang QJ; Chen L; Wang HY; Cao XC; Song NH; Lu Y
J Immunol Res; 2021; 2021():6686284. PubMed ID: 33688507
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
Albertini MR; Hank JA; Gadbaw B; Kostlevy J; Haldeman J; Schalch H; Gan J; Kim K; Eickhoff J; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2012 Dec; 61(12):2261-71. PubMed ID: 22678096
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
[TBL] [Abstract][Full Text] [Related]
15. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
16. PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
Zhang S; Chen K; Liu H; Jing C; Zhang X; Qu C; Yu S
J Immunother; 2021 Jul-Aug 01; 44(6):214-223. PubMed ID: 34028390
[TBL] [Abstract][Full Text] [Related]
17. Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival.
Khammari A; Knol AC; Nguyen JM; Bossard C; Denis MG; Pandolfino MC; Quéreux G; Bercegeay S; Dréno B
J Immunol Res; 2014; 2014():186212. PubMed ID: 24741578
[TBL] [Abstract][Full Text] [Related]
18. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
19. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
Hanniford D; Zhong J; Koetz L; Gaziel-Sovran A; Lackaye DJ; Shang S; Pavlick A; Shapiro R; Berman R; Darvishian F; Shao Y; Osman I; Hernando E
Clin Cancer Res; 2015 Nov; 21(21):4903-12. PubMed ID: 26089374
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma.
Thakur R; Laye JP; Lauss M; Diaz JMS; O'Shea SJ; Poźniak J; Filia A; Harland M; Gascoyne J; Randerson-Moor JA; Chan M; Mell T; Jönsson G; Bishop DT; Newton-Bishop J; Barrett JH; Nsengimana J
Clin Cancer Res; 2019 Dec; 25(24):7424-7435. PubMed ID: 31515461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
